

Correlation Between Blood Groups and Severe Anemia Among Anemia Patients in Sana'a City, Yemen

Amel Abdullah Almagrabi ^{2,4}, Fauid Hussein Ahmed Al-Hababi ², Khaled Abdulkarim Al-Moyed ³, Azhar Azher Mohammed Al-Ankoshy ⁶, Ola Ahmed Abdulwali Al-Sharjabi ³, Taghreed Mohammed Hameed Shaba ³, Ibrahim Ali Al-Arashi ⁵, Hassan Abdulwahab Al-Shamahy ^{3*}, Ahmed Mohammed Al-Haddad ¹

¹Department of Medical Laboratories, College of Medicine and Health Sciences, Hadhramout University, Al-Mukalla, Republic of Yemen.

²Yemeni Board for Medical and Health Specialties, Ministry of Health and Population, Republic of Yemen.

³Medical Microbiology and Clinical Immunology Department, Faculty of Medicine and Health Sciences, Sana'a University, Republic of Yemen.

⁴National center of Central Public health Laboratories, Ministry of Health and Population

⁵Medical Microbiology and Clinical Immunology Department, Faculty of Health Sciences, Tamar University, Republic of Yemen.

⁶Jabir ibn Hayyan Medical University, Faculty of Medicine, Iraq.

***Correspondence Author:** Hassan Abdulwahab Al-Shamahy, I. O., Medical Microbiology and Clinical Immunology Department, Faculty of Medicine and Health Sciences, Sana'a University, Republic of Yemen.

Received Date: September 22, 2025; **Accepted date:** October 03, 2025; **Published date:** October 10, 2025

Citation: Amel A. Almagrabi, Ahmed Al-Hababi FH, Khaled Abdulkarim Al-Moyed, Azhar Azher Mohammed Al-Ankoshy, Ola Ahmed Abdulwali Al-Sharjabi, et al, (2025), Correlation Between Blood Groups and Severe Anemia Among Anemia Patients in Sana'a City, Yemen, *Clinical Research and Studies*, 4(5); DOI:10.31579/2835-2882/095

Copyright: ©2025, Hassan Abdulwahab Al-Shamahy. this is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: Blood is a specialized connective tissue with a complete and unchangeable identity. It provides one of the means of communication between cells of different parts of the body and the external environment. In modern medicine, blood transfusion is an important procedure to replace blood loss. At least 30 common antigens and hundreds of other rare antigens have been found in human blood cells and shown to be linked to anemia and other diseases.

Objective: To determine the frequency of different types of anemia among patients who visit the three main specialized hospitals in the city of Sana'a and to determine the association of severe anemia with different blood types and Rh factors, as well as the association with gender and age groups with severe anemia.

Subjects and methods: A cross-sectional study was carried out among 391 patients suffering from anemia in Sana'a City from 1st October 2023 to the end of February 2024. Data on socio-demographics, clinical presentations, blood samples for hemoglobin level, and other blood markers were collected and tested by automated methods. Blood groups were determined using the glass slide method using antisera A, B, and D. Using SPSS version 25, descriptive statistical analysis and adjusted odds ratios were used to determine the associated factors.

Results: The male patients counted 61.1%, and the female patients counted 38.9%. The mean age of our patients was 17.3 years, with an SD of 18.7 years, and their ages ranged from 1 to 91 years. Most of our patients were in the age group of 1–5 years (30.4%), followed by the group of 11–15 years (18.7%). The mean hemoglobin level of our patients was 6.8 mg/dL and ranged from 3.0 to 10.8 mg/dL. Very severe anemia (<6.1 mg/dL) was reported in 26.1% of all patients. The predominant blood group was the O blood group (60.1%), followed by A (28.9%), while B and AB counted 7.9% and 3.1%, respectively. Considering Rh antigens, 91.3% of total patients were Rh+ and only 8.7% were Rh-. The most common anemia was thalassemia (30.2%), followed by sideroblastic anemia (22.8%), neonatal anemia (21%), and sickle cell anemia (16.1%). However, a low rate of anemia for chronic diseases (7.2%), pernicious anemia (1%), and aplastic anemia (0.6%) were recorded. There was no significant association between severe anemia and any blood groups or Rh factor. Also, there was no association between severe anemia occurrence and sex or age groups.

Conclusion: We can conclude that blood group O was dominant among our patients, and thalassemia, sideroblastic anemia (cortical anemia), neonatal anemia, and sickle cell anemia were the most common anemias in Sana'a city. There was no significant association between severe anemia and any blood group or Rh factor or the sex or age of the patients. There is a need to develop a good system for better detection, diagnosis, management, and treatment of anemia. Finally, anemia in this region has been shown to be a public health problem.

Key words: anemia; associated factors; blood group; hemoglobin; prevalence; sana'a city; severe anemia; yemen

Introduction

Blood is a unique type of connective tissue that has an absolute identity. It offers one way for the cells in various bodily components to communicate with the outside world [1]. Blood transfusions are a crucial part of modern medicine's strategy to replace lost blood [2]. Human blood cells have been shown to have hundreds of uncommon antigens in addition to at least 30 frequently occurring ones, particularly on the membrane surfaces of the cells. Since the majority of antigens are weak, their main significance comes from researching gene inheritance to determine paternity. Blood transfusion responses are far more likely to be caused by two specific antigen types than by the others. These are the Rh system and the O-A-B antigen system [3].

The two blood group antigens that are known to be clinically important are ABO and Rh. The fourth system to be identified was the rhesus blood group system 1. ABO blood group people are classified into four primary blood groups based on the presence of agglutinins and antigens: A, B, AB, and O. Blood types A and B have type A and type B antigens, respectively, but blood types O and O have neither type A nor type B antigens. Rhesus antigen, named for the monkeys who originally discovered a similar antigen, is present in 85%-90% of human red blood cells. Because Rh negative blood donors or those who are pregnant can be immunogenic to this blood type, it is the second most important blood group system. In addition to having RhD antigen on the surface of their red blood cells and organ transplants, people who are Rh positive are also associated with certain illnesses such as duodenal ulcer, diabetes mellitus, urinary tract infections, and neonatal Rh incompatibility 1-3. According to the World Health Organization's statistics on anemia worldwide, 1.62 billion individuals (95%), or 24.8% of the population, suffer from anemia. Additionally, according to WHO estimates, 20% of maternal and neonatal deaths in underdeveloped nations are caused by anemia 4,5. A disorder known as anemia is characterized by a low reduction in either the total hemoglobin level or the number of red blood cells. Anemia is defined by the World Health Organization (WHO) as Hb<130 g/L in men over the age of 15, 110 g/L in pregnant women, and <120 g/L in women who are not pregnant but older than 15 6,7. A clinical disease known as anemia is characterized by a drop in blood hemoglobin concentration that is below the average for the patient's age 2. It is a widespread issue that primarily affects the impoverished in developing nations 2,3. Adolescent anemia has a serious negative impact on a person's physical and mental development, as well as their ability to behave and think clearly, be physically fit, perform well at work, and even have a negative impact on the outcome of a pregnancy 1. Although oral iron supplements are frequently administered to treat anemia, they should only be used in cases when dietary interventions have proven ineffective. Additionally, an iron supplement helps treat anemia brought on by an iron deficit 4. In addition, oral iron supplements have the potential to exacerbate pre-existing ulcers and ulcerative colitis, as well as induce gastrointestinal issues such as nausea, vomiting, diarrhea, and constipation. Chronic iron supplementation may also contribute to heart disease. Due to decreased oxygen delivery and cellular oxidative capability, anemia may even be detrimental to athletic performance 6,8. Therefore, it would be preferable to treat those who are more susceptible to anemia in order to combat anemia. It would be simpler to recommend particular dietary recommendations to stop the occurrence of anemia in a

group if the specific demographic that is susceptible to or resistant to anemia has been identified.

Anemia can cause a variety of subtle symptoms, including weakness, fatigue, headaches, shortness of breath, and decreased activity capacity 9. Acute anemia symptoms can include dizziness, a sense of impending death, unconsciousness, and increased thirst 9. Before a person gets visibly pale, their anemia must be severe. The rate at which hemoglobin depletes determines the symptoms of anemia 10. Depending on the underlying cause, other symptoms could appear 9. The likelihood of requiring a blood transfusion after surgery can be elevated by preoperative anemia 11. Anemia can be mild to severe and be either transient or chronic 12. Blood loss, a reduction in red blood cell formation, and an increase in red blood cell destruction can all lead to anemia 9. Inflammation of the stomach or intestines, bleeding during surgery, severe injuries, and blood donation are among the causes of bleeding 9. Reduced production can be caused by thalassemia, iron shortage, vitamin B12 deficiency, and certain bone marrow cancers 9. Genetic conditions including sickle cell anemia, infections like malaria, and several autoimmune diseases are among the factors contributing to higher breakdown 9. The size of the red blood cells and the quantity of hemoglobin in each cell can also be used to categorize anemia. Anemia with small cells is known as microcytic anemia; anemia with large cells is known as macrocytic anemia; anemia with normal-sized cells is known as normocytic anemia. A hemoglobin level of less than 130 to 140 g/L (13 to 14 g/dL) for men and less than 120 to 130 g/L (12 to 13 g/dL) for women is required for the diagnosis of anemia 9,13. Then, additional testing is necessary to identify the cause 9,14. Several individuals with chronic disease-related anemia do not exhibit any active inflammation or dietary problems at the time of diagnosis. These include numerous with reduced limb loading, such as individuals with spinal cord injuries, space travelers, elderly people with restricted mobility, bedridden patients, and participants undergoing experimental bed rest 15. Iron supplementation is advantageous for preventive purposes for some populations, including pregnant women 9,16. It is not advised to take dietary supplements without first identifying the exact cause. Usually, a person's indications and symptoms determine whether or not blood transfusions are necessary. They are not advised for those who are asymptomatic unless their hemoglobin levels are 60 to 80 g/L (6 to 8 g/dL). Some patients who have severe bleeding may also benefit from following these suggestions. Agents that stimulate erythropoiesis should only be used in cases of severe anemia 9,17.

People with thalassemias are primarily linked to those from Mediterranean descent, Arabs (particularly Palestinians and those descended from them), and Asians. According to estimates, the prevalence is 1% in Thailand, 16% in Cyprus, and 3-8% in populations from Bangladesh, China, India, Malaysia, and Pakistan 18. An estimated 80-90 million individuals worldwide, or 1.5% of the total population, are estimated to be carriers of β -thalassemia 17. However, precise information on carrier rates in many groups is lacking, especially in poor nations where a high incidence is predicted or known to occur 19,20. Due to the disease's prevalence in nations where thalassemia is not well understood, getting a good diagnosis and treatment can be challenging 21.

Sickle cell illness usually manifests symptoms between the ages of 5 and 6 months. Numerous health issues could arise, including anemia, bacterial infections, stroke, hand and foot edema, and pain episodes (sometimes referred to as sickle cell crises). As people age, chronic discomfort may occur 22,23. In the developed world, the typical lifespan is between 40 and 60 years. Sickle cell illness affects every important organ. The sickle cell's aberrant actions and improper passage through the small blood channels can also cause harm to the liver, heart, kidneys, gallbladder, eyes, bones, and joints. A person with sickle cell disease receives two faulty copies of the β -globin gene, one from each parent, which produces hemoglobin 24. It is found on chromosome 11. Depending on the precise mutation in each hemoglobin gene, there are a number of subtypes. Variations in temperature, stress, dehydration, and high altitude can all trigger an attack 22. Millions of people worldwide suffer with sickle cell disease, with a higher frequency in sub-Saharan Africa, the Western Hemisphere's Spanish-speaking nations (South America, the Caribbean, and Central America), Saudi Arabia, India, and Mediterranean nations like Turkey, Greece, and Italy 25.

This study aimed to determine the frequency of different types of anemia among patients who visit the three main specialized hospitals in the city of Sana'a and to determine the association of severe anemia with different blood types and Rh factors, as well as the association with sex and age groups with severe anemia.

Subjects And Methods

Study design:

A cross-sectional study was carried out among 391 patients suffering from anemia in Sana'a City from 1st October, 2023 to the end of February 2024.

Sample size:

A sample size of 391 was calculated using the following parameters: confidence level=95%, margin of error =3.81%, and frequency of anemia among general population in similar areas=18% 9,11.

Data collection:

Individual data were collected in a pre-designed questionnaire, including, clinical data, demographic data, and laboratory results.

Statistical analysis

By using Epi Info statistical program version 6 (CDC, Atlanta, USA), the analysis of the data was performed. Expressing the quantitative data as mean values, or standard deviation (SD), when the data was normally distributed. Expressing the qualitative data as percentages. Associated factors were calculated by 2X2 tables to find odds ratio, confidence interval, X² and p value.

Ethical consideration:

Prior to gathering data, the institution's ethical review committee gave its approval. All participants or/and their guardians received an explanation of the study's goals and advantages prior to involvement, and their verbal informed agreement was obtained. Participants and their families were also told that their participation was optional and that they might decline it without giving a reason.

Fields and laboratory works:

From 1st October 2023, to the end of February 2024, a cross-sectional study centered in selected tertiary hospitals in Sana'a city was carried out, enrolling 391 anemia patients. Direct interviewing and review of medical records were used to gather socio-demographic and clinical data. Each participant provided a venous blood sample to determine blood markers and for blood group detection.

Results

Table 1 shows sex and age distribution of anemia patients attending the main tertiary hospitals in Sana'a city. The male patient's counts 61.1% and female patients was 38.9%. The mean age of our patients was 17.3 years with standard division (SD) equal to 18.7 years and ages ranged from 1-91 years. Most of our patients were in the age group of 1-5 years (30.4%), followed by the group of 11-15 years (18.7%), while other age groups were less frequent.

Characters	N (%)
Sex	
Male	239 (61.1)
Female	152 (38.9)
Age groups (years)	
1-5	119 (30.4)
6-10	64 (16.4)
11-15	73 (18.7)
16-20	32 (8.2)
>20	103 (26.3)
Total	391 (100)
Mean age	17.3 years
SD	18.7 years
Median	11 years
Mode	1 year
Min-Max	1-91 years

Table 1: Sex and Age distribution of anemia patients in Sana'a city

Table 2 shows the hemoglobin level in anemia patients whom attending hospitals, Sana'a city, Yemen. The mean hemoglobin level of our patients was 6.8 mg/dL, the SD level was 1.3 mg/dL and the level ranged from 3.0 to

10.8 mg/dL. Very severe anemia (<6.1 mg/dL) was reported in 26.1% of all patients.

Characters	Total N (%)
HGB (mg/dL)	
Less than 6.1	102 (26.1)
6.1-7	120 (30.7)
7.1-8	105 (26.9)
8.1-9	45 (11.5)
9.1-10	15 (3.8)
>10	4 (1.02)
Total	391 (100)
Mean	6.8 mg/dL
SD	1.3 mg/dL
Median	6.9 mg/dL
Mode	6.1 mg/dL
Min-Max	3.0-10.8 mg/dL

Table 2: Hemoglobin (HGB) level of anemic patients at a tertiary hospital in Sana'a city

Table 3 shows the frequency of different blood groups in anemic patients in Sana'a city. The predominant blood group was O blood group counted 60.1%, followed by A blood group counted 28.9%, while B blood group only

counted 7.9% and AB was 3.1%. Considering Rh antigens 91.3% of total patients were Rh+ and only 8.7% were Rh-.

Blood groups	N (%)
A+	103 (26.3)
A-	10 (2.6)
Total A	113 (28.9)
B+	27 (6.9)
B-	4 (1.02)
Total B	31 (7.9)
AB+	12 (3.1)
AB-	0 (0.0)
Total AB	12 (3.1)
O+	215 (55)
O-	20 (5.1)
Total O	235 (60.1)
Rh +	357 (91.3)
Rh -	34 (8.7)
Total	391 (100)

Table 3: The frequency of different blood groups in anemic patients in Sana'a city

Table 4 shows the frequency of different types of anemia diagnosed among our study group at a tertiary hospitals in Sana'a city. The most common anemia was thalassemia (30.2%), followed by sidroplastic anemia (22.8%),

neonatal anemia (21%) and sickle cell anemia (16.1%). However low rate of anemia of chronic diseases (7.2%), pernicious anemia (1%) and aplastic anemia (0.6%) were recorded.

Type of anemia	N (%)
Aplastic anemia	2 (0.6)
Anemia of chronic diseases	28 (7.2)
Neonatal anemia	82 (21)
Pernicious anemia	4 (1)
Severe acute malnutrition	1 (0.3)
Sickle cell anemia	63 (16.1)
Septicemia anemia	1 (0.3)
Sidroplastic anemia	89 (22.8)
Thalassemia	118 (30.2)
Others	3(0.9)
Total	391 (100)

Table 4: The frequency of different types of anemia diagnosed among the study group at a tertiary hospitals in Sana'a city

Table 5 shows the association between blood groups and sever anemia, there was no significant association between severe anemia and any blood groups and Rh factor.

Blood groups	N (%)	Severe anemia (n=102)	OR	95% CI	X ²	P value
A+	103 (26.3)	25 (24.3)	0.8	0.5-1.4	0.2	0.6
A-	10 (2.6)	0 (0.0)	0	0-0.9	3.6	0.06
Total A	113 (28.9)	25 (22.1)	0.78	0.4-1.2	1.15	0.2
B+	27 (6.9)	6 (22.2)	0.79	0.3-2	0.2	0.63
B-	4 (1.02)	2 (50)	2.8	0.3-20	1.1	0.27
Total B	31 (7.9)	8 (25.8)	0.99	0.25-3.6	0.007	0.92
AB+	12 (3.1)	3 (25)	0.9	0.25-3.5	0.007	0.93
AB-	0 (0.0)	0 (0.0)	0	0.0-1.13	3.1	0.07
Total AB	12 (3.1)	3 (25)	0.9	0.2-3.5	0.007	0.13
O+	215 (55)	61 (28.4)	1.1	0.8-2.1	1.2	0.25
O-	20 (5.1)	5 (25)	0.94	0.33-2.6	0.01	0.91
Total O	235 (60.1)	66 (28.1)	1.3	0.8-2.1	1.2	0.2
Rh+	357 (91.3)	95 (26.6)	1.3	0.56-3.3	0.58	0.44
Rh-	34 (8.7)	7 (20.6)	0.7	0.3-1.6	0.5	0.44
Total	391 (100)	102 (26.1)	-	-	-	-

Table 5: Severe anemia associated with blood groups and Rh factor

Table 6 shows severe anemia associated risk factors with sex and age groups. Considering sex as associated factors, there was no association between severe anemia occurrence and sex. Also, there was no significant association between severe anemia occurrence and any age groups.

Characters	Severe Anemia (n=102) N (%)	OR	CI	X ²	p
Sex					
Male (n=239)	64 (26.8)	1.1	0.6-1.9	0.15	0.63
Female (n=152)	38 (25)	0.9	0.5-1.4	0.15	0.69
Age groups (years)					
1-5 (n=119)	38 (31.9)	1.3	0.8-2	1.3	0.24
6-10 (n=64)	18 (28.1)	1.1	0.6-2.0	0.16	0.68
11-15 (n=73)	23 (31.5)	1.39	0.79-2.4	1.3	0.24
16-20 (n=32)	4 (12.5)	0.3	0.1-1.1	3.3	0.06
>20 (n=103)	19 (18.4)	0.66	0.38-1.2	2.0	0.15

Table 6: Severe anemia associated risk factors (sex and age).

Discussion

We found that the O blood group accounted for 60.1% of the total blood count, followed by the A blood group at 28.9%, the B blood group at 7.9%, and the AB blood group at 3.1%. These results were differ from those of Reshmarani et al. 26 in India, where blood group B had the highest distribution (34.3%), followed by blood groups O and A (31% and 22.7%, respectively), and blood group AB (11%), which had the lowest percentage frequency.

In our study, blood group O had the highest prevalence of severe anemia (28%), followed by blood group B (25%). A study by Reshmarani et al. found and documented a different pattern in the prevalence of blood types (B>O>A>AB) among anemic individuals 26. Blood type O has been reported to be the most often occurring blood group with anemia in numerous other research. In our analysis, there were 8.7% Rh-ve and roughly 91.3% Rh+ve.

In other investigations, where Rh+ counts for more than 90% of all blood types, similar distribution patterns were also noted 1-4. According to these findings, different populations have different frequencies of ABO and rhesus blood groups depending on their ethnic backgrounds 3 7. However, no such correlation was found between the Rh factor and the incidence of anemia in the populations listed above. Adolescent anemia has a detrimental effect on

many areas of life, including behavior, cognitive development, physical fitness, employment performance, and even the risk of an unfavorable pregnancy outcome. Mild anemia is known to lower immunological competence and has a negative impact on productivity.

In the current study, thalassemia (30.2%) was the most common type of anemia detected in our patient population. Thalassemia is inherited blood illness, which cause abnormal hemoglobin 27. Depending on the kind of thalassemia, symptoms might range from mild to severe 22. Because thalassemia can impact both the formation and lifespan of red blood cells, mild to severe anemia (few red blood cells or hemoglobin) is frequently present 22.

Yemen and other Mediterranean peoples are home to a high prevalence of beta type thalassemia 28. 25,000 people died from thalassemia in 2013, compared to 36,000 in 1990 29.

South Asians, who live far from the Mediterranean, are also impacted; the Maldives has the greatest concentration of carriers worldwide (16–18% of the population) 30. People of Mediterranean descent, Arabs (particularly Palestinians and those descended from them), and Asians are disproportionately linked to thalassemia 31. The incidence is believed to be 16% in Cyprus, 1% in Thailand, and 3-8% in Bangladeshi, Chinese, Indian, Malaysian, and Pakistani populations 18. An estimated 80-90 million

persons worldwide, or 1.5% of the total population, are estimated to be β thalassemia carriers 19.

According to the current study, sideroplastic anemia affected 22.8% of Yemenis. When the bone marrow creates ringed sideroblasts instead of healthy red blood cells (erythrocytes), the condition known as sideroplastic anemia, also known as sideroachrestic anemia, occurs 32. Anemia of prematurity stems from both intrinsic and iatrogenic factors, leading to over 80% of extremely preterm infants requiring red blood cell transfusions within the first month of life. In the first few weeks of life, preterm newborns frequently suffer from anemia and significant blood losses as a result of repeated laboratory tests 33,34.

Sickle cell anemia ranked as the fourth most frequent kind of anemia in the current survey, accounting for 16.1% of cases. This substantial rate of sickle cell anemia reflects the disease's widespread distribution worldwide and specifically in our region 35. Millions of people suffer from sickle cell disease worldwide; sub-Saharan Africa, Spanish-speaking areas of the Western Hemisphere (South America, the Caribbean, and Central America), Saudi Arabia, India, and Mediterranean nations like Yemen, Turkey, Greece, and Italy have higher rates of the disease 36. It caused roughly 114,800 fatalities in 2015 37.

In this study, there were 2 (0.6%) cases of aplastic anemia. The severe hematologic disorder known as aplastic anemia is caused by the body's inability to produce enough red blood cells 38. Numerous cancer syndromes and cancer are linked to aplastic anemia. Stem cells that live in the bone marrow create blood cells 39. Red blood cells, white blood cells, and platelets are all in low quantity as a result of aplastic anemia 40. The elderly are also prone to it, but those in their teens and twenties experience it most frequently. It may be brought on by immunological disorders, toxins, medications, radiation, or hereditary factors. However, in about half of cases, the cause is unknown 40,41.

4.8 Study Limitations

A number of constraints need to be noted. First, generalizability to different healthcare settings may be limited by the single-center architecture. Second, cytogenetic and molecular analyses which are becoming more and more crucial for a thorough hematological diagnosis were left out. Third, there was no rigorous evaluation of inter-observer heterogeneity in PBF interpretation. Fourth, because only patients undergoing BMA were included, selection bias might be present. Although recent studies have examined the prevalence of pancytopenia among HIV patients 42, red blood cell allografting and autoimmunity in patients with transfusion-dependent sickle cell anemia 43, evaluation of complete blood count parameters in pregnant women with preeclampsia 44, and evaluation of serum zinc levels among Yemeni patients with sickle cell anemia 45. Additionally, the recovery time course of peripheral blood counts during induction therapy for acute lymphoblastic leukemia in children, the trends and causes of morbidity in a portion of children in Sana'a City, Yemen 46,47, and the correlation between hemodialysis patients' hepcidin levels, serum iron status, and markers of micro-inflammation 48. This is the first study discussed the blood groups and anemia in Yemen.

Conclusion and recommendations:

We conclude that blood group O was dominant among our patients, and thalassemia, sideroplastic anemia (cortical anemia), neonatal anemia, and sickle cell anemia were the most common anemias in Sana'a city. There was no significant association between severe anemia and any blood group or Rh factor or the sex or age of the patients. There is a need to develop a good

system for better detection, diagnosis, management, and treatment of anemia. Finally, anemia in this region has been shown to be a public health problem.

References

1. Kaur M. (2015). Relationship and distribution of ABO, Rh blood groups and hemoglobin concentration among the adolescents *J Phys Pharm Adv* 5(9):703-712.
2. Myers DJ, Collins RA. (2025). Blood Donation. 2024 Oct 7. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.
3. Hall JE, Vaz, M, Raj T. (2016). Guyton & Hall Textbook of Medical Physiology: Second South Asia Edition. Elsevier.
4. Kumar BA, Kaushik M. (2013). Blood group and anemia: Exploring a new relationship. *Journal of Public Health and Epidemiology* 5(1):43-45.
5. Harvey P (2004). A strategic approach to anemia control, MOST, The USAID micronutrients program, Arlington, Virginia.
6. IDallal S. (2016). Iron Deficiency Anemia: A Short Review, *Journal of Cancer Research and Immuno-Oncology* 2(1):1000106.
7. Goddard AF, James MW, McIntyre AS, Scott BB. (2011). Guidelines for the management of iron deficiency anaemia. *Gut* 60:1309-1316.
8. Zhang AS, Enns CA. (2009). Molecular mechanisms of normal iron homeostasis. *Hematology. Am Soc Hematol Educ Program* 1:207-214.
9. Janz TG, Johnson RL, Rubenstein SD. (2013). Anemia in the emergency department: evaluation and treatment. *Emergency Medicine Practice* 15(11): 1-15, quiz 15-16.
10. Anemia-NHLBI, NIH".www.nhlbi.nih.gov. Retrieved 8 February 2025.
11. Ng O, Keeler BD, Mishra A, et al. (2019). Iron therapy for preoperative anaemia. *Cochrane Database of Systematic Reviews* 12: CD011588.
12. Anemia - Symptoms and causes. Mayo Clinic. Retrieved 1 April 2025.
13. Smith RE. (2010). The clinical and economic burden of anemia. *The American Journal of Managed Care* 16:S59-66.
14. Rhodes CE, Denault D, Varacallo MA. (2025). Physiology, Oxygen Transport. 2022 Nov 14. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.
15. Payne MW, Uthoff HK, Trudel G. (2007). Anemia of immobility: Caused by adipocyte accumulation in bone marrow. *Medical Hypotheses* 69(4):778-786.
16. Bhutta ZA, Das JK, Rizvi A, et al. (2013). Evidence-based interventions for improvement of maternal and child nutrition: what can be done and at what cost?. *Lancet* 382(9890):452-477.
17. Qaseem A, Humphrey LL, Fitterman N, Starkey M, Shekelle P. (2013). Treatment of anemia in patients with heart disease: a clinical practice guideline from the American College of Physicians. *Annals of Internal Medicine* 159(11):770-779.
18. Sharma DC, Arya A, Kishor P, Woike P, Bindal J. (2017). Overview on thalassemias: A review article. *Med. res. chronicles [Internet]*. [cited 2025 Jul 17]; 4(03):325-37.
19. Galanello, R, Origa R. (2010). Beta-thalassemia. *Orphanet Journal of Rare Diseases* 5(1):11.

20. Vichinsky, EP. (2005). Changing Patterns of Thalassemia Worldwide. *Annals of the New York Academy of Sciences* 1054(1):18-22.
21. Weatherall DJ. (2005). Keynote address: The challenge of thalassemia for the developing countries. *Annals of the New York Academy of Sciences* 1054(1):11–17.
22. What are the signs and symptoms of sickle cell disease? National Heart, Lung, and Blood Institute. 12 June 2015. Archived from the original on 9 March 2016. Retrieved 8 March 2016.
23. What is sickle cell disease? National Heart, Lung, and Blood Institute. 12 June 2015. Archived from the original on 6 March 2016. Retrieved 8 March 2016.
24. What causes sickle cell disease? National Heart, Lung, and Blood Institute. 12 June 2015. Archived from the original on 24 March 2016. Retrieved 8 March 2016.
25. Data and statistics on sickle cell disease. Centers for Disease Control and Prevention 2022.
26. Reshmarani SN, Subhash C. (2019). A Study of correlation between blood groups and anemia in young adults. *International Journal of Physiology* 7(4):199-202.
27. Papadakis MA, Tierney LM, McPhee SJ. Sideroblastic anemia. *Current Medical Diagnosis and Treatment* 2006. McGraw-Hill Medical. ISBN:978-0-07-145410-0.
28. Greer, JP, Arber, DA, Glader B, et al. (2013). *Wintrobe's Clinical Hematology*. Wolters Kluwer, Lippincott Williams & Wilkins Health. ISBN:9781451172683.
29. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the global burden of disease study 2013. *Lancet* 2014; 385 (9963):117-171.
30. Waheed F, Fisher C, Awofeso A, Stanley D. (2016). Carrier screening for beta-thalassemia in the Maldives: perceptions of parents of affected children who did not take part in screening and its consequences. *J Community Genet* 7(3):243-253.
31. Goljan EF (2010). *Pathology*, 2nd ed. Mosby Elsevier, Rapid Review Series.
32. Caudill JS, Imran H, Porcher JC, Steensma DP. (2008). Congenital sideroblastic anemia associated with germline polymorphisms reducing expression of FECH. *Haematologica* 93(10):1582-1584.
33. Widness JA. (2008). Pathophysiology of anemia during the neonatal period, including anemia of prematurity. *NeoReviews* 9(11):e520-e525.
34. Holzapfel LF, Rysavy MA, Bell EF. (2023). Red blood cell transfusion thresholds for anemia of prematurity. *Neoreviews* 24(6):e370-e376.
35. Vos T, Barber RM, Bell B, et al. (2015). Global Burden of Disease Study 2013 Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the global burden of disease study 2013. *Lancet* 2015; 386(9995):743-800.
36. CDC (2022). Data & Statistics on Sickle Cell Disease - CDC. Centers for Disease Control and Prevention. Retrieved 3 April 2024.
37. Wang H, Naghavi M, Allen C, et al. (2015). Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet* 388(10053):1459-1544.
38. Adams M, Benitz W, Geaghan S, et al. Reduction in red blood cell transfusions using a bedside analyzer in extremely low birth weight infants. *Journal of Perinatology* 2005; 25:21-25.
39. Astruc D, Donato L, Haddad J, Matis J, Messer J. Early treatment of premature infants with recombinant human erythropoietin. *Pediatrics* 1993; 92(4):519-523.
40. Connolly N, Cress G, Johnson K, et al. Phlebotomy overdraw in the neonatal intensive care nursery. *Pediatrics* 2000; 106(2):19.
41. Obladen M, Sachsenweger M, Stahnke M. Blood sampling in very low birth weight infants receiving different levels of intensive care. *Eur J Pediatr*. 1988; 147(4):399-404. doi:10.1007/BF00496419. PMID:3396595.
42. Al-Babeli, I. A. A., Hajar, M. A., Salem, A. K., & Al-Shamahy, H. A. (2025). Prevalence of Pancytopenia among HIV Patients Attended to HIV Center in Sana'a City. *Sana'a University Journal of Medicine and Health Sciences*, 19(3), 210–215. <https://doi.org/10.59628/jchm.v19i3.1597>
43. Al-Nuzaili, M. A., & Sharaf-Aldin, M. Y. (2025). Red Cell Alloimmunization and Autoimmunization in Transfusion Dependent Sickle Cell Disease Patients at the Yemeni Society of Thalassemia and Genetic Blood Disorders in Sana'a City, Yemen. *Sana'a University Journal of Medicine and Health Sciences*, 19(3), 222–226. <https://doi.org/10.59628/jchm.v19i3.1584>
44. AL- Gunied , A. S. A. B., Salem, A. K., Allow , A. . K., & Al-Shamahy, H. A. (2025). Evaluation of the Complete blood count Parameters in pregnant women presenting With Preeclampsia in AL-Gomhori Hospital Sana'a, Yemen. *Sana'a University Journal of Medicine and Health Sciences*, 19(2), 181–185. <https://doi.org/10.59628/jchm.v19i2.1636>
45. Al-Jamali , B. A. A. K., Salem, A. K., Hajar , M. A., & Al-Shamahy, H. A. (2025). Evaluation of Serum Zinc Level among Yemeni Patients with Sickle Cell Anemia . *Sana'a University Journal of Medicine and Health Sciences*, 19(2), 186–191. <https://doi.org/10.59628/jchm.v19i2.1638>.
46. Al-Shamahy, H. A., and A. A. Ishak. “Trends and causes of morbidity in part of children in the city of Sana'a, Yemen 1978-2018: findings of single children's health center”. *Universal Journal of Pharmaceutical Research*, vol. 5, no. 6, Jan. 2021, doi:10.22270/ujpr.v5i6.504.
47. El-Zine, M. A. Y., R. Hamayun, A. M. Alhadi, M. A. A. Ali, and H. A. Al-Shamahy. “Peripheral blood count recovery time course during induction treatment for acute lymphoblastic leukemia in children”. *Universal Journal of Pharmaceutical Research*, vol. 9, no. 3, July 2024, doi:10.22270/ujpr.v9i3.1110.
48. Mufadhal, E. A., F. K. Al-Showafi, H. A. Al-Shamahy, and E. M. Al-zabidi. “The association between levels of hepcidin, iron status and micro-inflammation markers among haemodialysis”. *Universal Journal of Pharmaceutical Research*, vol. 4, no. 5, Nov. 2019, doi:10.22270/ujpr.v4i5.313.

Ready to submit your research? Choose ClinicSearch and benefit from:

- fast, convenient online submission
- rigorous peer review by experienced research in your field
- rapid publication on acceptance
- authors retain copyrights
- unique DOI for all articles
- immediate, unrestricted online access

At ClinicSearch, research is always in progress.

Learn more <https://clinicsearchonline.org/journals/clinical-research-and-studies->



© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.